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EDITORIAL COMMENT
Why Is Aortic
Sclerosis Associated With
Adverse Clinical Outcomes?*
Catherine M. Otto, MD
Seattle, Washington
Calcific aortic valve disease encompasses a range of disease
severity from mild leaflet thickening without valve obstruc-
tion, called “aortic sclerosis,” to severe aortic stenosis. It is
intuitive that severe obstruction in blood flow at the valve
level results in poor clinical outcomes and that relief from
the obstruction by valve replacement corrects the problem.
However, we now recognize that milder degrees of calcific
valve disease are also associated with adverse clinical out-
comes. In the absence of altered valve hemodynamics, the
mechanism of this association is not obvious.
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Aortic sclerosis is diagnosed on echocardiography as focal
areas of increased echogenicity on the valve leaflets with
normal valve motion and a normal, or only mildly increased,
antegrade velocity across the valve. Definitions vary slightly,
but typically an outflow velocity2.5 or2.0 m/s is used to
separate sclerosis from mild stenosis. Aortic valve sclerosis is
a common finding on echocardiography; in population-
based studies, aortic sclerosis is present in about 25% of
adults over 65 years of age (1–3). Aortic valve sclerosis is
associated with many of the same “risk factors” as coronary
artery disease (CAD). Clinical factors associated with aortic
sclerosis include age, male gender, hypertension, elevated
serum levels of lipoprotein(a) and low-density lipoprotein
(LDL), smoking, and diabetes (1,3–5).
At the tissue level, aortic sclerosis is characterized by focal
areas of subendothelial thickening on the aortic side of the
valve leaflet. The normal aortic valve leaflet consists of three
well-defined layers: the fibrosa is the central dense collagen
layer that provides tensile strength to the leaflet; the
ventricularis is an elastin-rich layer on the ventricular side of
the leaflet; and the spongiosa is a layer of loose connective
tissue typically confined to the basal one-third of the leaflet.
The lesions of aortic sclerosis displace the subendothelial
elastic lamina on the aortic side of the leaflet and extend into
the adjacent fibrosa. It is presumed that endothelial disrup-
tion related to altered shear stress on the aortic side of the
leaflet may initiate the disease process, although there is no
direct evidence for this hypothesis.
The early lesions of aortic sclerosis have many similarities
with atherosclerosis. There is prominent accumulation of
LDL and lipoprotein(a), with evidence of LDL oxidation
(6–8). An inflammatory cell infiltrate is present, composed
of macrophages, with some foam cells, and T-lymphocytes.
The lipids and inflammatory cells co-localize with areas of
microscopic calcification, and a subset of macrophages
produces proteins, such as osteopontin, that are involved in
tissue calcification. Phenotypic cellular changes occur, in-
cluding evidence of calcifying vascular cells and demonstra-
tion of an osteoblast phenotype (9,10). Aortic sclerosis
lesions also contain angiotensin-converting enzyme with
local production of angiotensin II (11). Other components
of the lesion include overexpression of tenascin C and
alterations in the expression of matrix metalloproteinases
(12–14). Animal models of calcific aortic valve disease
suggest that both cell proliferation and apoptosis are in-
volved in the disease process (15,16).
The presence of aortic sclerosis is associated with adverse
clinical outcomes, and this association is present even when
baseline factors such as cardiac risk factors and known
atherosclerotic disease are taken into account (17). In the
Cardiovascular Health Study of over 5,000 adults over age
65 years followed up for approximately five years, aortic
sclerosis was associated with a 40% increase in the risk of
myocardial infarction and a trend toward an increased risk
of angina, heart failure, and stroke in patients without
known cardiovascular disease at study entry. In patients with
no known CAD at study entry, there was a 50% increase in
the risk of cardiovascular death (17). The association be-
tween mild valve disease and adverse clinical outcomes has
been observed in other studies (18), and this association is
not specific to the aortic valve, with adverse outcomes also
associated with mitral annular calcification at a similar risk
level (19–21).
Unfortunately, although epidemiologic studies are the
best approach for establishing associations, they provide
little insight into the mechanism of these associations.
There are several possible causes of adverse outcomes in
adults with aortic valve sclerosis. First, disease progression
in the valve leaflets may lead to increased leaflet stiffness
with valve obstruction (e.g., aortic stenosis). In a study of
over 2,000 patients with aortic sclerosis, progression to
aortic stenosis occurred in 16% (22). However, most devel-
oped only mild stenosis, and in the 2.5% of patients who
developed severe stenosis, the average time interval from
diagnosis of aortic sclerosis to severe aortic stenosis was
eight years, a longer time frame than encompassed by the
epidemiologic studies showing the association between
aortic sclerosis and clinical outcome. The rate of hemody-
namic progression of aortic stenosis in prospective studies
also suggests that valve obstruction is unlikely to be the
cause of adverse outcomes in patients with aortic sclerosis
(23,24).
The second hypothesis is that aortic sclerosis is simply a
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marker of subclinical CAD. Support for this mechanism
includes the association between aortic sclerosis and athero-
sclerosis of the aorta (3,20) and the observation that about
50% of adults undergoing aortic valve replacement for severe
aortic stenosis also have concurrent significant CAD.
The third hypothesis is that both aortic sclerosis and
atherosclerosis are the result of a common underlying
pathophysiologic mechanism such as inflammation. In this
issue of the Journal, Chandra et al. (25) tested this hypoth-
esis by comparing inflammatory markers and CAD in
patients with and without aortic sclerosis who presented to
the emergency department with chest pain. Aortic sclerosis
was present in 49% of these 415 patients, a higher preva-
lence than seen in population-based studies, most likely due
to the selection of patients with cardiac symptoms. Even
with this relatively small number of patients, there was an
increased rate of cardiovascular events, defined as cardiovas-
cular death or CAD, at one year in those with aortic
sclerosis compared with those with a normal valve (16.8%
vs. 7.1%, p  0.002), supporting the association seen in
population-based studies. Coronary artery disease was
present in 76% of all patients, with a similar prevalence in
those with and without aortic sclerosis.
Aortic sclerosis was also associated with increased serum
levels of C-reactive protein and fibrinogen, with the risk of
cardiovascular death or CAD increasing with each tertile of
C-reactive protein. On multivariate analysis, clinical out-
come was predicted by the presence of CAD, myocardial
infarction at the index admission, C-reactive protein levels,
congestive heart failure, and age but not by the presence of
aortic sclerosis. The authors conclude that adverse outcomes
in patients with aortic sclerosis are related to the presence of
CAD and systemic inflammation.
The observation that aortic sclerosis predicts clinical
outcome in a group of symptomatic patients with a high
prevalence of CAD is of particular interest because in the
Cardiovascular Health Study, the association between aortic
sclerosis and clinical outcome was observed only in those
subjects without known CAD. The association of aortic
sclerosis with elevated inflammatory markers is consistent
with other studies and suggests that inflammation may play
a role in the disease process (26). However, these data still
do not unequivocally prove that inflammation is the cause of
adverse clinical outcomes in patients with aortic sclerosis.
Another potential underlying mechanism that might
explain adverse outcomes in aortic sclerosis patients includes
endothelial dysfunction, as suggested by the finding of
reduced brachial artery flow-mediated dilation in patients
with aortic sclerosis (27). Other proposed mechanisms
include genetic polymorphisms of the vitamin D receptor,
leading to altered tissue calcification (28), and apolipopro-
tein A1, B, and E polymorphisms (29), leading to increased
lipid accumulation in the valve leaflets. The important of
lipid accumulation in this disease process is highlighted by
several small retrospective studies showing that lower serum
LDL levels or treatment with lipid-lowering therapy is
associated with a slower rate of disease progression in
calcific aortic valve disease (30–33).
Thus, to date it remains unclear whether the mechanism
of the association between aortic sclerosis and adverse
clinical outcomes is diffuse atherosclerosis, inflammation,
endothelial dysfunction, altered calcium metabolism, lipid
accumulation, genetic polymorphisms, or other, as-yet-
undefined, factors. Ultimately, proof of a cause-effect rela-
tionship will require a prospective randomized intervention
trial in which blocking the proposed pathway results in a
reduction in adverse clinical outcomes.
Despite the similarities between calcific aortic valve dis-
ease and atherosclerosis, there are distinct differences in
these disease processes. Many patients with significant
CAD do not have aortic valve disease and vice versa. In
patients with CAD, clinical events often are due to plaque
rupture, whereas there is little evidence for plaque instability
or thrombus formation on the sclerotic aortic valve leaflets.
Exploring the differences between these similar, but not
identical, disease processes may enhance our understanding
of both conditions.
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